Reuters logo
BRIEF-Axsome Therapeutics says ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome expected year-end 2017​
2017年9月7日 / 中午11点45分 / 3 个月前

BRIEF-Axsome Therapeutics says ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome expected year-end 2017​

Sept 7 (Reuters) - Axsome Therapeutics Inc

* Axsome Therapeutics - ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome (CRPS) is expected year-end 2017​

* Axsome Therapeutics Inc - ‍interim analysis results for Coast-1 are now also expected late December 2017 to early January 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below